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Abstract Parkinson’s disease (PD) is a neurodegenerative
movement disorder. Although there is no cure, symptomatic
treatments are available and can significantly improve
quality of life. The motor, or movement, features of PD
are caused by reduced production of the neurotransmit-
ter dopamine. Dopamine deficiency is most often treated
using dopamine replacement therapy. However, this therapy
can itself lead to further motor abnormalities referred to
as dyskinesia. Dyskinesia consists of involuntary jerking
movements and muscle spasms, which can often be violent.
To minimise dyskinesia, it is necessary to accurately titrate
the amount of medication given and monitor a patient’s
movements. In this paper, we describe a new home monitor-
ing device that allows dyskinesia to be measured as a patient
goes about their daily activities, providing information that
can assist clinicians when making changes to medication
regimens. The device uses a predictive model of dyskinesia
that was trained by an evolutionary algorithm, and achieves
AUC>0.9whendiscriminatingclinically significant dyskinesia.
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Introduction
Parkinson’s Disease (PD) is a common, progressive neu-
rodegenerative condition affecting approximately 1% of
those over 65 years of age. The motor features of PD
are caused by degeneration of dopamine-producing neu-
rones in the basal ganglia. A lack of dopamine leads to
a number of motor abnormalities, including slowed move-
ments with smaller amplitude (bradykinesia), stiffness and
tremor. Motor features of PD can be treated through the
use of dopamine replacement drugs, such as levodopa. Over
time, prolonged exposure to dopamine replacement ther-
apy, combined with the neurodegenerative changes of PD,
can lead to dyskinesia: involuntary jerking and spasms of
the muscles that can affect the whole body, and can be
very severe. Dyskinesia is common; for example, it affects
90% of patients with PD treated with levodopa after ten
years [2]. Despite this, the exact pathophysiological basis of
dyskinesia is unknown [26].
To reduce the risk of dyskinesia, clinicians attempt to
administer drugs at the lowest dose required to treat the
motor features of PD. As PD worsens over time, the dose
required to treat the motor features increases. The risk of
inducing dyskinesia, or making it more severe and more pro-
longed in someone who already has it, is increased if too
high a dose is prescribed. Most patients see their clinician
relatively infrequently, and medication changes only tend to
occur at the time of review. Additionally, studies have shown
that people with PD are often unaware of when they have
dyskinesia [28] and that patient-completed symptom diaries
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tend to lack accuracy [10]. This means it is very difficult for
clinicians to know when in the day dyskinesia is occurring,
motivating the need for automated methods of monitoring
dyskinesia that may be used in the patient’s own home.
In this paper, we describe a new home monitoring device
that uses a predictive model to identify episodes of dyskine-
sia from accelerometry time series data. Predictive models
are computational or mathematical models that can pre-
dict the characteristics of previously unseen data [13, 18].
[1] review previous work on applying these approaches to
movement data collected from PD patients, and [22] give
a more general account of the use of wearable devices for
objectively assessing PD motor symptoms. A number of
previous studies have considered methods for identifying
dyskinesia in movement data [3, 5, 11, 16, 23, 27]; a com-
mon aspect is the use of spectral features to characterise
dyskinesia [5, 16, 23, 27], focusing on the low frequency
bands where dyskinetic activity generally occurs. The main
difference in our work lies in the use of raw acceleration
data to build predictive models. This provides more infor-
mation for the training algorithm to work with. It also makes
relatively few assumptions about the physiological appear-
ance of dyskinesia, which is important given the limited
understanding of this movement [26]. Since our algorithm
uses symbolic mathematical expressions to characterise
movements in the time domain, it is able to discriminate
movements based on their overall shape, rather than their
frequencies [19, 20], which is useful for discriminating
dyskinesia from other low-frequency movements.
Materials and methods
Devices
To measure a patient’s movements, we used sensing mod-
ules comprising a tri-axial accelerometer and tri-axial
gryoscope (see Fig. 1). The modules have a sample rate of
100Hz, and are able to store data in local memory. In the
clinical studies, this data was downloaded to a computer for
further processing following each recording session. In the
final version of the product, it is anticipated that the data will
be intermittently broadcast to an Android mobile phone,
where the data will be input to the predictive model and the
resulting measures of dyskinetic activity broadcast to the
patient’s clinician. The sensing modules are lightweight and
wireless, allowing for patients to move freely and perform
their usual daily activities. They were fitted to each patient’s
legs, arms, torso, head and trunk using adjustable bands.
During the clinical study periods, we also made use
of an infrared video camera, which recorded footage of
each patient during the time their movements were being
measured. This allowed associations to be made between
the accelerometry data and the patient’s activities when
labelling periods of movement in the data set.
Clinical study data
Twenty three PD patients were involved in two clinical stud-
ies: the first involved 6 patients, and the second involved
17. Table 1 gives the demographics of the two study groups.
The patients in both groups were broadly similar, although
the initial group of patients were on average slightly older
with more severe motor and dyskinesia scores. The move-
ments of each patient were recorded continuously over a
period of hours: 6 for the first group, 2 for the second group.
Patients were recorded sequentially, and all patients within a
single study wore the same set of sensor modules. However,
the two studies used different sets of sensor modules, and
this provides a useful source of diversity when assessing the
generality of the predictive models.
To be included in the study, patients required an estab-
lished diagnosis of PD according to internationally recog-
nised criteria [14] and had to have displayed evidence of
dyskinesia during a hospital outpatient clinic consultation
performed by a Consultant Neurologist with a specialist
interest in movement disorders (SJ, JA). Those who did
not meet these criteria, or those with PD and cognitive
impairment sufficient enough to prevent their ability to pro-
vide informed consent, were excluded. Patients completed
demographic details and the 26-item Parkinson Disease
Dyskinesia Scale (PDYS-26), a patient-completed measure
of the impact of dyskinesia on quality of life (range 0–104,
higher numbers indicate greater impact) [15]. The sensors
were attached and the video camera was activated. Every
hour, motor signs were assessed using the MDS Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) motor
examination (range 0–132, higher numbers indicate greater
impairment) [9]. Between times, patients were free to move
around the unit, although were asked to remain in view of
the video camera. No changes were made to medication reg-
imens and so patients were predominately assessed in the
ON state. The application of the sensors was not related to
the timing of medications. Some patients with unpredictable
ON/OFF fluctuations demonstrated both medication states
during the recording period. All patients gave informed con-
sent and both studies were granted ethical approval by the
National Research Ethics Service (IRAS 84044) and local
Research and Development approval from Leeds Teaching
Hospitals NHS Trust. The study was added to the NIHR
Clinical Research Network (CRN) portfolio (ID 11762).
Following data collection, the video footage was watched
by three trained clinicians (JA, JC, PDC), who marked up
segments of the video and graded the intensity of dyskine-
sia in each of the assessed body parts according to Part 3 of
the Unified Dyskinesia Rating Scale (UDysRS) [8], which
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Fig. 1 Six degrees of freedom
wearable accelerometer and
gyroscope sensor modules used
in this study
grades dyskinesia from 0 (no dyskinesia) to 4 (incapacitat-
ing dyskinesia which prohibits some postures and voluntary
movements). Where raters disagreed on the severity of the
dyskinesia, the average grade was taken.
Table 2 summarises the data collected during the two
studies. Data from the first study was used to compare
different classifier models and the utility of different data
sources, and then to select a promising classifier from
amongst all the trained instances for use in the deployed
system. Data from the second study was used to give an
unbiased estimate of the generality of this selected classifier
on the wider population of patients and sensors.
Genetic programming
Evolutionary algorithms (EAs) are a family of general purpose
optimisation algorithms, or metaheuristics, that are moti-
vated by biological evolution [6]. They are known to work
well in large complex search spaces, which makes themwell
suited to biomedical problems. EAs carry out a series of
moves (known as mutation and crossover) through a solu-
tion search space by making changes to a group of existing
candidate solutions that are held in a data structure called a
Table 1 Summary of the two clinical studies
Study 1 Study 2
Number of patients 6 17
Assessment period (hours) 6 2
Gender male:female 4:2 11:6
Age (years) 71±8.9 65±7.3
Disease duration (years) 9.8±3.7 8.1±3.6
MDS-UPDRS motor score 31±19.1 28±18.0
PDYS-26 quality of life score 37.6±29.2 34.7±24.5
population. EAs are iterative: they begin with a population
of random solutions, and at each iteration (or generation), a
new population is created by applying moves to a subset of
the previous generation’s population. This subset is chosen
by a selection mechanism, which selects existing solutions
in proportion to their objective value (or fitness).
Genetic programming (GP) is an EA that optimises exe-
cutable expressions [24]. In this work, we use GP to find
a mathematical expression that describes the relationship
between one or more input variables and a target variable.
The input variables, in this case, are the input accelerometry
values within a window of time series data. The target vari-
able is the degree of dyskinesia that is associated with the
time series window; hence, GP is used to find mathemat-
ical expressions that describe patterns of acceleration that
are indicative of dyskinesia. There are various kinds of GP
[24]. In this work, we use Cartesian GP, where an expression
is laid out as a grid of functional elements. Cartesian GP
has been shown to be competitive against other GP systems
[21]. We use a particular variant called implicit context rep-
resentation Cartesian GP (IRCGP), which uses a low-level
representation that is designed to improve the effectiveness
of crossover [4].
Table 2 Number of examples of each dyskinesia grade collected from
the two studies
UDysRS Study 1 Study 2
0 2933 1747
1 1227 971
2 1688 562
3 681 183
4 64 361
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Fig. 2 Illustration of how a
symbolic mathematical
expression trained using IRCGP
is used to classify an
acceleration time series,
showing how the expression is
applied to inputs taken from a
sliding window. The final
classification is the mean of the
outputs from each window
Classifier models
IRCGP was used to train a symbolic mathematical expres-
sion comprised of up to 36 function instances, selected
from the set {+, −, ×, ÷,mean,min,max, abs}, laid out on
a 6×6 Cartesian plane and taking inputs from 32 termi-
nal nodes fed from the accelerometry data (see Fig. 2). We
used a population size of 200, a generation limit of 100, and
standard mutation and crossover probabilities [19].
For each data item, a univariate time series was first
created by calculating the magnitude of acceleration at
each time index. During classification, a sliding window of
length 32 (0.32s) is slid along a time series, and the classi-
fier generates an output for each of the L − 31 overlapping
windows, where L is the length of the time series. The clas-
sification for the time series is then taken to be the mean
of these values, i.e. the mean occurrence of the movement
pattern which is described by the symbolic mathematical
expression. By applying a threshold to the output range of
the classifer, a particular data item can then be classified as
either dyskinetic or not dyskinetic.
For comparative purposes, we also trained long-term and
short-term spectral classifiers. For the long-term model,
the mathematical expression operates on spectral densities
from 32 equally spaced intervals in the frequency range 0–
50Hz, calculated using the method described in [12]. For
the short-term spectral classifier, the expression is applied
independently to the spectral densities in each time series
window, and then averaged. To make the results directly
comparable, these models were formulated such that the
evolutionary algorithm searches a space of equal size and
dimensionality for each classifier model.
Results and analysis
All classifiers were assessed using the area under the
receiver operating characteristic (ROC) curve, or AUC,
when discriminating samples of Grade 3 and 4 dyskinesia
from movement samples with no dyskinesia. AUC can be
interpreted as the probability that a randomly drawn sam-
ple will be allocated to the correct category [17]. In general,
Fig. 3 Discriminative ability of
classifiers trained to recognise
Grade 3 and 4 dyskinesia,
comparing the predictive ability
of time domain and spectral
domain classifiers and the utility
of accelerometry and rotational
(gyroscopic) data. Notched box
plots show distributions of AUC
on the test set over 50
independent runs of IRCGP
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Fig. 4 ROC curves for the
selected dyskinesia classifier on
the second study data set,
showing discriminative ability
(a) for the different UDysRS
dyskinesia grades, (b) when the
patient is carrying out different
kinds of activity. Coloured
regions show confidence
boundaries determined through
repeated re-sampling
we have found that it is easier to generate robust classi-
fiers when Grades 1 and 2 are not used during training.
This is possibly due to difficulty in clinically differentiating
between these grades of dyskinesia using the UDysRS.
Figure 3 compares the different classifier models. It
can be seen that time domain classifiers have significantly
higher AUCs than spectral classifiers, reaching AUCs in
excess of 0.9 on the test set. Figure 3 also compares the util-
ity of accelerometry and rotational gryroscope data when
training classifiers, showing that more accurate classifiers
can be built from accelerometry data. These results suggest
that it is easier to find significant discriminatory patterns in
Fig. 5 Mapping between
dyskinesia grade and classifier
outputs on the second study
data. Horizontal grey lines show
the optimal thresholds in the
classifier’s output range for
differentiating between classes,
and the red text gives the
corresponding values of
sensitivity and specificity for
each clinical grade of dyskinesia
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Fig. 6 Ability of spectral
classifiers with highest test set
score to discriminate dyskinesia
whilst walking
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the time domain than in the spectral domain, and that pat-
terns may be more evident in planar movements rather than
rotational movements.
The classifier instance with the highest test set AUC was
selected for further study. To obtain a more robust measure
of generality, it was re-evaluated using the movement sam-
ples in the second data set. Figure 4a shows the resulting
ROC curves, illustrating that the classifier retains a good
ability to separate samples with Grades 3 and 4 dyskinesia
from samples with no dyskinesia, and has not overfitted the
first data set. Figure 5 shows the actual mapping between
labelled samples and classifier outputs, indicating that the
outputs for the higher dyskinesia grades are clearly sepa-
rated from those for samples with no dyskinesia. There is
some overlap, but this is mostly due to a long tail of outliers
in the non-dyskinesia samples. This reflects the observation,
also seen in other studies, that certain voluntary movements
are very difficult to discriminate from dyskinesia. As an
example of this, Fig. 4b compares the discriminative ability
of the classifier when a patient is sitting or walking. Walk-
ing, in this case, is a low frequency activity, and degrades
the accuracy of the classifier. Nevertheless, as Fig. 6 shows,
the classifier performs a lot better than the spectral domain
classifiers in this respect, indicating the benefit of working
in the time domain when discriminating activities of similar
spectral frequencies.
The selected classifier has since been integrated into a
tool for clinical use, and Fig. 7 shows an example of the
output generated when using the tool to evaluate a de novo
patient who was not included in the two studies. This sum-
mary chart is intended to give clinicians a quick overview of
a patient’s response to levodopa over a period of 24 hours,
showing when they are experiencing clinically significant
degrees of dyskinesia. In this example, the patient experiences
two hours of Grade 3 or Grade 4 dyskinesia between 12:00 and
14:00, which might suggest to the clinician that the levodopa
dose given at 12:00 is too great and requires reduction.
In addition to direct use as a clinical tool, the classifiers
can also be used to improve understanding of dyskinesia. In
particular, it is possible to visualise the discriminatory pat-
tern of acceleration that is being recognised by the classifier.
As an example of this, Fig. 8 plots the means of windows
of data which are assigned a particularly high value by the
classifier, i.e. periods of movement that the classifier iden-
tifies as being particularly dyskinetic. It indicates a pattern
comprising two periods of rising then falling acceleration,
with the second period of rise and fall being shorter than
the first. There is also a prominent dip at the top of the first
peak, forming a caldera shape. Whilst the meaning of this
pattern is currently unclear, it is well conserved across the
data samples, suggesting that it is a significant discriminator
of dyskinesia from other movements.
Fig. 7 An example of output generated by the system, showing a sum-
mary chart for a patient measured over a 24 hour period. The red dots
represent the time at which medication was taken, the dark green lines
the occurrence of severe dyskinesia (grade 4) and the light green lines,
significant dyskinesia (grade 3). The purple line indicates when the
patient is asleep
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Fig. 8 Visualisation of the acceleration pattern recognised by the best
performing dyskinesia classifier. Mean acceleration patterns are shown
for the 10, 100 and 1000 time series windows that generated the highest
outputs
Conclusions
In this paper, we have described our work on developing a
wearable home monitoring system for assessing dyskinesia
in Parkinson’s disease patients. The results demonstrate the
ability of the system to reliably detect clinically significant
dyskinesia, thus providing the information required by clin-
icians to adjust a patient’s medication and more effectively
manage the troublesome side-effects that currently reduce
the quality of life of many patients. Our system also has the
potential to significantly reduce the clinical costs of man-
aging Parkinson’s disease, estimated to be around $12000
per patient in the year following diagnosis [25], and with
the potential to save over £84 million per annum in England
alone [7].
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